Group 1 - The announcement highlights the potential increase in costs for investors using cash substitution to subscribe to the fund due to the upcoming Spring Festival holiday, which may lead to higher accrued interest on substituted securities [1] - Investors are advised to consider direct trading or physical subscription methods to avoid increased costs associated with cash substitution during the holiday period [1] Group 2 - The announcement states that from February 13, 2026, China International Capital Corporation will be added as a broker for subscription and redemption services for certain funds managed by the company [4] - Investors can consult details through the company's customer service or website [4] Group 3 - A communication-based meeting for the fund's shareholders will be held, with voting starting from February 25, 2026, to May 25, 2026 [8][9] - The meeting will discuss the proposal for the continuous operation of the fund, which has seen its net asset value fall below 50 million yuan for 60 consecutive working days [33][34]

Core Viewpoint - The company plans to utilize part of its temporarily idle raised funds for cash management, aiming to enhance the efficiency of fund usage and increase asset returns while ensuring the safety of the raised funds and the normal implementation of investment projects [2][20]. Investment Overview - **Investment Purpose**: The objective is to improve the efficiency of raised fund usage and increase returns for the company and its shareholders while ensuring the safety of the funds and the normal progress of investment projects [3]. - **Investment Amount and Duration**: The company intends to use no more than RMB 219 million (including principal) for cash management, with a usage period not exceeding 12 months from the date of board approval [4][9]. - **Source of Funds**: The funds for this cash management come from the temporarily idle raised funds from the company's initial public offering, which raised a total of RMB 2,189.73 million, with a net amount of RMB 2,006.56 million after deducting issuance costs [5][6]. Investment Method - **Types of Investment Products**: The company will invest in high-safety, liquid, short-term products (including but not limited to structured deposits and large-denomination certificates of deposit), ensuring that these funds are not used for pledging or securities investments [8][10]. - **Implementation Method**: The board authorizes the chairman to make investment decisions and sign relevant documents within the approved investment amount and duration, with the finance department responsible for implementation [10]. Cash Management Returns - **Distribution of Returns**: The returns from cash management will belong to the company and will be prioritized for supplementing any shortfall in investment amounts for projects, adhering to regulatory requirements [11]. Recent Cash Management Situation - **Previous Cash Management**: In the last 12 months, the company has approved the use of up to RMB 670 million for cash management, with a similar 12-month usage period [13]. Risk Analysis and Control Measures - **Investment Risks**: While the company invests in high-safety and liquid products, it acknowledges that market fluctuations can impact these investments [17]. - **Risk Control Measures**: The company will adhere to relevant regulations and internal policies, conduct timely analysis of investment products, and ensure regular audits to safeguard fund usage [18]. Impact on the Company - The cash management initiative will not affect the normal operation of the company's daily funds or the implementation of investment projects, and it aims to enhance fund efficiency and returns for shareholders [20]. Opinions of Intermediary Institutions - The sponsor institution has confirmed that the cash management plan has been approved by the board and complies with relevant regulations, emphasizing that it will not alter the intended use of raised funds [22].

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 证券代码：601995 证券简称：中金公司 公告编号：临2026-009 ■ 1 本公告所述"担保金额""担保余额"及"担保总额"在计算时仅包含固定利率票据的本金及利息以及浮动 利率票据的本金；浮动利率票据利息需根据实际情况确定。本公告所载金额涉及汇率的，均按照2026年 1月31日人民币兑美元、人民币兑港币汇率折算。 ● 累计担保情况 ■ 中国国际金融（国际）有限公司（曾用名"中国国际金融（香港）有限公司"，以下简称"中金国际"）为 中国国际金融股份有限公司（以下简称"公司"或"中金公司"）直接持股的全资子公司。中金国际直接持 有CICC Hong Kong Finance 2016 MTN Limited（以下简称"发行人"或"被担保人"）100%的股权。发行人 于2016年5月5日设立了境外中期票据计划（以下简称"中期票据计划"）。截至本公告披露日，该中期票 据计划下可发行的票据本金最高额为100亿美元。中金国际作为发行人的唯一股东，为发行人在中期票 据计划下的发行提供担保。 中国国际金融股份有限公司 关于间接持股全资子公司发行中 ...

Core Viewpoint - In 2026, China's economy is expected to experience moderate policy support and a structural focus on both "increase and decrease" and "supply and demand" to achieve reasonable growth [1][4] Macroeconomic Outlook - The macroeconomic policy is crucial for maintaining stable economic operations and achieving high-quality development. The People's Bank of China plans to implement a moderately loose monetary policy in 2026, enhancing counter-cyclical and cross-cyclical adjustments to support the "14th Five-Year Plan" [2] - The core drivers of economic growth in 2026 are expected to be a combination of policy-driven investment, domestic demand recovery, and resilient exports, forming a multi-faceted growth structure [3][4] A-share Market Performance - The A-share market is anticipated to stabilize around the 4000-point mark, which has shifted from a historical resistance level to a significant support level. Key drivers include policy and liquidity support, improvement in corporate earnings, and increased market confidence [5][6] - The overall profit growth rate for A-shares is projected to rise from 6% in 2025 to between 8% and 14% in 2026, with a notable recovery in non-financial corporate earnings [6] International Gold Price Trends - The international gold price is expected to continue its upward trend, with the London gold price experiencing a significant increase of 13.01% in January 2026, reaching above $5000 per ounce [8] - Factors supporting the rise in gold prices include the Federal Reserve's interest rate cuts, ongoing central bank gold purchases, and geopolitical tensions, with expectations for gold prices to potentially reach between $5500 and $6000 per ounce in 2026 [9]

Group 1 - Eli Lilly's GLP-1/GIP drug Tirzepatide (brand name: Mounjaro) has received approval from the National Medical Products Administration of China for use as a monotherapy in adults with type 2 diabetes, based on the SURPASS-CN-MONO study targeting early patients in China, which is expected to expand market potential in the country [1] - Eli Lilly's IL-23 monoclonal antibody, both intravenous and subcutaneous formulations, has been approved for the treatment of Crohn's disease and ulcerative colitis, enhancing its position in the immunology sector [1] Group 2 - In Q4 2025, Eli Lilly reported revenue of $19.29 billion, a 43% year-over-year increase, exceeding market expectations; adjusted earnings per share were $7.54, up 42% [2] - The Tirzepatide product line generated $36.5 billion in revenue for the year, making it the highest-selling drug globally; the company provided an optimistic revenue guidance for 2026, expecting a range of $80 billion to $83 billion, representing approximately a 25% year-over-year growth [2] Group 3 - Following the positive earnings report and product developments, Eli Lilly's stock experienced significant volatility, with a single-day increase of 10.33% on February 4, 2026, closing at $1,107.12; however, the stock closed at $1,015.21 on February 11, 2026, down 0.96%, with a total decline of 8.30% over the past five trading days, indicating a short-term market adjustment after the positive news [3] Group 4 - CICC released a report on February 10, 2026, noting that Tirzepatide has become the "king of drugs" in 2025, and Eli Lilly has a robust pipeline, with the oral GLP-1 drug Orforglipron expected to receive approval in Q2 2026, which could serve as a new growth driver; the report maintains a neutral rating with a target price of $1,107 [4] - Institutional data shows that 78% of market opinions are buy or hold, reflecting confidence in the long-term prospects of the GLP-1 sector [4]

Core Viewpoint - The competition in the overseas market for Chinese securities firms is intensifying, with leading players dominating the Hong Kong IPO market, while many smaller firms struggle to establish a foothold. Group 1: Overseas Expansion Efforts - As of February 11, 2026, four securities firms have disclosed their latest progress in overseas business, including Huatai Securities and GF Securities, which are issuing zero-coupon convertible bonds to support their international operations [2][4] - Northeast Securities and Huawan Securities have received approval to establish and increase capital in their Hong Kong subsidiaries, with each committing HKD 500 million [3][4] Group 2: Competitive Landscape - The "Matthew Effect" is evident in the overseas competition, with leading firms like CITIC Securities and CICC capturing a significant share of the Hong Kong IPO market, accounting for 53.96% of the total fundraising, while smaller firms have less than 1% [5][6] - Head firms have expanded into derivatives and broader international markets, establishing a 24-hour global trading system, while smaller firms face higher barriers to entry and slower internationalization processes [6][7] Group 3: Strategic Differentiation - The industry consensus is that while the pace of overseas expansion varies, it is essential for firms to explore differentiated development paths. Leading firms should leverage their capital strength and extensive client networks, while smaller firms should focus on niche markets or specialized financial products [8][9] - Smaller firms are exploring opportunities in cross-border services, wealth management, and Southeast Asian markets, capitalizing on their understanding of domestic policies and established trust with local enterprises [9]

Core Viewpoint - The storage industry is experiencing a vibrant ecosystem in the Hong Kong stock market, driven by the ongoing storage bull market and the influx of A+H listings, with companies like Juchen Technology and Lanke Technology successfully listing in Hong Kong [1] Group 1: Company Overview - Juchen Technology has been deeply engaged in the storage chip sector for over 16 years, evolving into a leading global designer of high-performance non-volatile storage chips [2] - The company has established three core business lines: storage chips, mixed-signal chips, and NFC chips [2] Group 2: Revenue Contribution - Storage chips are the company's primary revenue driver, contributing 88.5% of total revenue in the first three quarters of 2025, while mixed-signal chips and NFC chips contributed 8.9% and 2.6%, respectively [3] - The product matrix for storage chips includes modules supporting DDR2 to DDR5, high-reliability chips for automotive and industrial applications, and consumer electronics chips [3][4] Group 3: Market Position - Juchen Technology ranks first in China and third globally in the EEPROM market, with a projected global market share of approximately 14.0% in 2024 [4] - The company is the second-largest global supplier of DDR5 SPD chips, with a market share exceeding 40% in 2024 [4] Group 4: Financial Performance - Total revenue increased from 703 million RMB in 2023 to 1.028 billion RMB in 2024, with a year-on-year growth of 21.29% in the first three quarters of 2025 [5][6] - Adjusted net profit rose from 141 million RMB in 2023 to 298 million RMB in 2024, reflecting a growth rate of 110.7% [6] Group 5: Profitability and Efficiency - The company's gross margin improved from 46.6% in 2023 to 59.8% in the first three quarters of 2025, driven by a higher proportion of high-value products and improved pricing power [6][8] - The adjusted net profit margin increased from 20.1% in 2023 to 32.3% in the first three quarters of 2025, indicating enhanced operational efficiency [6][8] Group 6: Market Dynamics - The current storage "super bull market" is driven by the AI computing revolution, leading to a structural supply-demand imbalance, particularly for high-bandwidth memory (HBM) and DDR5 [9][10] - The demand for SPD chips is expected to significantly increase as AI servers require more memory modules, with DDR5 prices rising over 307% since September 2025 [11][12] Group 7: Future Outlook - Juchen Technology anticipates significant growth in DDR5 SPD chip demand in the second half of 2026, while also expanding its product line with VPD chips for next-generation storage devices [12] - The company faces challenges such as high customer concentration, with the largest customer accounting for 41.1% of revenue, and reliance on external suppliers for wafer manufacturing [14]

Market Performance - Kolunbotai Biotech-B (06990.HK) experienced a decline of 3.33% on February 12, 2026, closing at HKD 423.40 with a trading volume of HKD 208 million, influenced by a general market downturn [1] - The Hang Seng Index fell by 0.86%, and the Hang Seng Tech Index dropped by 1.65%, with the biotechnology sector down by 0.84%, reflecting a decrease in market risk appetite affecting high-valuation biotech stocks [1] Institutional Insights - Bank of America Securities raised the target price for the company from HKD 470 to HKD 479 but maintained a "Neutral" rating, adjusting the annual treatment cost assumption for Sac-TMT (Lukangshatu Zhunzai) downwards, leading to a 5% and 6% reduction in revenue forecasts for 2026 and 2027 respectively, which may raise concerns about the product's commercialization profitability [2] Financial and Technical Analysis - Technical indicators show weakness, with the stock price falling below the 5-day moving average of HKD 428.2, and the MACD divergence value at -2.862, indicating insufficient bullish momentum [3] - There was a net outflow of HKD 11.09 million from major funds, while retail investors saw a net inflow of HKD 1.96 million, suggesting a cautious attitude from larger investors [3] Company Valuation - The company's price-to-earnings ratio (TTM) stands at -124.68, and the price-to-book ratio is 17.96, significantly higher than traditional pharmaceutical companies [4] - Despite the approval of the fourth indication for Sac-TMT (HR+/HER2- breast cancer) and its inclusion in the medical insurance list, increased competition in the TROP2 ADC space (e.g., AstraZeneca/Daiichi Sankyo's Enhertu) raises concerns about its long-term pricing advantage [4] Recent Company Status - CICC maintains an "Outperform" rating with a target price of HKD 550, but key catalysts for 2026, such as the FDA application for Sac-TMT and new clinical data, have yet to materialize, resulting in a lack of significant positive drivers for the stock price in the short term [5]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列中國國際金融股份有限公司（「本公司」）在上海證券交易所網站刊登的本公司關於 間接持股全資子公司發行中期票據並由直接持股全資子公司提供擔保的公告，僅供參 閱。 承董事會命 中國國際金融股份有限公司 董事會秘書 梁東擎 中國，北京 2026年2月12日 於本公告日期，本公司執行董事為陳亮先生及王曙光先生；非執行董事為張薇女士、 孔令岩先生及田汀女士；以及獨立非執行董事為吳港平先生、陸正飛先生、彼得 • 諾蘭先 生及周禹先生。 China International Capital Corporation Limited 中 國 國 際 金 融 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：03908） 海外監管公告 证券代码：601995 证券简称：中金公司 公告编号：临 2026-009 中国国 ...

每经AI快讯，中金公司2月12日晚间发布公告称，本次担保前，公司及控股子公司的担保总额为人民币 231.26亿元，占公司截至2024年12月31日经审计净资产的比例为20.05%。本次担保发生后，公司及控股 子公司的担保总额约为人民币328.81亿元，占公司截至2024年12月31日经审计净资产的比例约为 28.51%。 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经头条（nbdtoutiao）——打造百万元级尊界的江淮，迎来葛卫东、方文艳联手投资：两人各掏10亿 元，公司股价应声大涨！复盘历史：牛散参与定增有赚也有亏 （记者 张明双） ...